Mineral bone disorder in chronic kidney disease: Head-to-head comparison of the 5/6 nephrectomy and adenine models

BMC Nephrology

Volumn 15, Issue 1, 2014, Pages

  Ferrari, Guaraciaba O ^a   Ferreira, Juliana C ^a   Cavallari, Raquel T ^a   Neves, Katia R ^a   Dos Reis, Luciene M ^a   Dominguez, Wagner V ^a   Oliveira, Elizabeth C ^a   Graciolli, Fabiana G ^a   Passlick Deetjen, Jutta ^b   Jorgetti, Vanda ^a   Moysés, Rosa M A ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Bone disease; Chronic kidney disease; Hyperparathyroidism; Phosphate binder; Vascular calcification

Indexed keywords

CALCITRIOL; CALCIUM ION; COLECALCIFEROL; CREATININE; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE; ADENINE; CALCIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL CALCIFICATION; BONE; BONE DISEASE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE CLEARANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FOOD INTAKE; HUMAN; MALE; MORPHOMETRICS; NEPHRECTOMY; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PROTEIN BLOOD LEVEL; RAT; ANIMAL; BONE DISEASES, METABOLIC; BONE MINERALIZATION; COMPARATIVE STUDY; DISEASE MODEL; METABOLISM; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; WISTAR RAT;

ADENINE; ANIMALS; BONE DISEASES, METABOLIC; CALCIFICATION, PHYSIOLOGIC; CALCIUM; DISEASE MODELS, ANIMAL; MALE; NEPHRECTOMY; PHOSPHATES; RATS; RATS, WISTAR; RENAL INSUFFICIENCY, CHRONIC;

EID: 84900388119     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-15-69     Document Type: Article

References (25)

1. Improving global outcomes (KDIGO) CKD-MBD work group KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Disease, Kidney Int Suppl 2009 113 1 S130 19644521
2. Experimental renal insufficiency produced by partial nephrectomy. Chauntin A, Ferris EB, Arch Intern Med 1932 49 767 787 10.1001/archinte.1932. 00150120057006
3. Vascular calcification in animal models of CKD: a review. Shobeiri N, Adams MA, Holden RM, Am J Nephrol 2010 31 471 481 10.1159/000299794 20413965
4. Metabolic effects of dietary purine in rats. Yokozawa T, Oura T, Okada T, J Nutr Sci Vitaminol 1982 28 519 526 10.3177/jnsv.28.519 7161649
5. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. Katsumata K, Kusano K, Hirata M, Tsunemi K, Nagano N, Burke SK, Fukushima N, Kidney Int 2003 64 441 450 10.1046/j.1523-1755.2003.00126.x 12846739
6. Severe Hyperparathyroidism with bone abnormalities and metastatic calcifications in rats with adenine-induced uraemia. Tamagaki K, Yuan Q, Ohkawa H, Imazeki I, Moriguchi Y, Imai N, Sasaki S, Takeda K, Fukagawa M, Nephrol Dial Transplant 2006 21 651 659 10.1093/ndt/gfi273 16311258
7. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Nagano N, Myata S, Abe M, Kobayashi N, Wakita S, Yamashita T, Wada M, Kidney Int 2006 69 531 537 10.1038/sj.ki.5000020 16395276
8. Effects of thyroid hormone administration and estrogen deficiency on bone mass of female rats. Gouveia CH, Jorgetti V, Bianco AC, J Bone Miner Res 1997 12 2098 2107 10.1359/jbmr.1997.12.12.2098 9421243
9. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G, Kidney Int 2006 69 1945 1953 10.1038/sj.ki.5000414 16641930
10. Standardized symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Maluche H, Meunier PJ, Ott SM, Recker RR, Parfitt AM, J Bone Miner Res 2013 28 2 17 10.1002/jbmr.1805 23197339
11. A reproducible model for chronic renal failure in the mouse. Gagnon RF, Duguid WP, Urol Res 1983 11 11 14 10.1007/BF00272702 6857877
12. Comparison of chronic renal failure rats and modification of the preparation protocol as a hyperphosphataemia model. Terai K, Mizukami K, Okada M, Nephrology 2008 13 139 146 10.1111/j.1440-1797.2007.00844.x 18275502
13. Role of dietary phosphorus and degree of uremia in the development of renal bone disease in rats. Oste L, Behets G, Dams G, Bervoets AR, Marynissen RL, Geryl H, van Hoof VO, de Broe ME, D'Haese PC, Ren Fail 2007 29 1 12 10.1080/08860220601038637 17365904
14. Sevelamer hydrochloride, a calcium free phosphate binder, inhibits parathyroid cell proliferation in partially nephrectomized rats. Nagano N, Myiata S, Obana S, Kobayashi N, Abe M, Fukushima N, Wada M, Nephrol Dial Transplant 2003 18 3 81 85
15. Treatment of experimental renal osteodystrophy with pamidronate. Jokihaara J, Porsti IH, Koobi P, Jolma PM, Mustonem JT, Saha HH, Sievanen H, Kannus P, Iwaniec UT, Turner RT, Jarvinen TL, Kidney Int 2008 74 319 327 10.1038/ki.2008.180 18463610
16. Phosphorus overload and PTH induce aortic expression of Runx2 in experimental uraemia. Graciolli FG, Neves KR, dos Reis LM, Graciolli RG, Noronha IL, Moysés RM, Jorgetti V, Nephrol Dial Transplant 2009 24 5 1416 1421 10.1093/ndt/gfn686 19075196
17. Long-term treatment with lanthanum carbonate reduces mineral and bone abnormalities in rats with chronic renal failure. Damment S, Secker R, Shen V, Lorenzo V, Rodriguez M, Nephrol Dial Transplant 2011 26 1803 1812 10.1093/ndt/gfq682 21098011
18. Adequate phosphate binding with lanthanum carbonate attenuates arterial calcification in chronic renal failure rats. Neven E, Dams G, Postnov A, Postnov A, Chen B, de Clerck N, de Bro ME, D'Haese PC, Persy V, Nephrol Diet Transplant 2009 14 1 10
19. A rat model of chronic kidney disease-mineral bone disorder. Moe S, Chen N, Seifert MF, Sinders RM, Duan D, Chen X, Liang Y, Radcliff JS, White KE, Gattone VH 2nd, Kidney Int 2009 75 176 184 10.1038/ki.2008.456 18800026
20. Motor and behavioral changes in rats with adenine-induced chronic renal failure: influence of acacia gum treatment. Ali BH, Ziada A, Al Husseni I, Beegam S, Nemmar A, Exp Biol Med 2011 236 1 107 112 10.1258/ebm.2010.010163
21. NF-κB activation mediates crystal translocation and interstitial inflammation in adenine overload nephropathy. Okabe C, Borges RL, de Almeida DC, Fanelli C, Barlette GP, Machado FG, Arias SC, Malheiros DM, Camara NO, Zatz R, Fujihara CK, Am J Physiol Renal Physiol 2013 15 305(2) 155 F163
22. Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy. Sabbagh Y, Graciolli FG, O'Brien S, Tang W, dos Reis LM, Ryan S, Phillips L, Boulanger J, Song W, Bracken C, Liu S, Ledbetter S, Dechow P, Canziani ME, Carvalho AB, Jorgetti V, Moyses RM, Schiavi SC, J Bone Miner Res 2012 27 8 1757 1772 10.1002/jbmr.1630 22492547
23. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. Stubbs JR, He N, Idiculla A, Gilihan R, Liu S, David V, Hong Y, Quarles LD, J Bone Miner Res 2012 27 1 38 46 10.1002/jbmr.516 22031097
24. Purinergic signaling and bone remodeling. Orris I, Burnstock G, Arnett T, Curr Opin Pharmacol 2010 10 3 322 330 10.1016/j.coph.2010.01.003 20189453
25. Sevelamer Hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Cozzolino M, Staniforth M, Liapis H, Finch J, Burke SK, Dusso AS, Slatopolsky E, Kidney Int 2003 64 1653 1661 10.1046/j.1523-1755.2003.00284.x 14531797